Altimmune, INC 8-K filings

Altimmune announced its second quarter 2026 financial results, highlighting the initiation of the global PERFORMA Phase 3 MASH trial and positive topline data from the RECLAIM Phase 2 AUD trial, alongside a robust cash balance.

Altimmune announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder, meeting primary and key secondary endpoints.

Altimmune announced its first quarter 2026 financial results, highlighting a strengthened balance sheet with over $535 million in cash and plans to initiate its PERFORMA Phase 3 MASH trial in the second half of 2026.

Altimmune, Inc. has closed a public offering of common stock and warrants, raising approximately $211.2 million in net proceeds to fund clinical development.

Altimmune shareholders approved an increase in authorized common stock to 400 million shares at the 2026 Annual Meeting.

Altimmune, Inc. announced its fourth quarter and full-year 2025 financial results, highlighted by positive MASH trial data, FDA Breakthrough Therapy Designation, and plans for a Phase 3 MASH trial in 2026.

Altimmune, Inc. announced the date for its 2026 Annual Meeting of Stockholders and updated deadlines for stockholder proposals and director nominations.

Altimmune, Inc. announced a registered direct offering of common stock and pre-funded warrants, raising approximately $75 million in gross proceeds from a new institutional investor.

Altimmune, Inc. announced positive 48-week topline results from its IMPACT Phase 2b trial of pemvidutide for MASH, showing statistically significant improvements in fibrosis markers and weight loss.

Altimmune, Inc. announces a planned CEO transition, with Jerome Durso succeeding Vipin K. Garg, Ph.D., effective January 1, 2026, to lead the company into its next phase of growth.

Altimmune, Inc. has initiated a new at-the-market equity offering program to sell up to $200 million of common stock, replacing a previous $150 million program.

Altimmune, Inc. announced an expanded debt facility with Hercules Capital, increased cash reserves, and significant progress in its MASH, AUD, and ALD clinical programs, alongside key executive appointments.

Altimmune, Inc. announced the appointment of Christophe Arbet-Engels as its new Chief Medical Officer, with former CMO Dr. Scott Harris transitioning to a Senior Strategic Advisor role.

Altimmune, Inc. announced that all proposals, including director elections and auditor ratification, were approved by stockholders at its 2025 Annual Meeting.

Altimmune, Inc. announced positive second quarter 2025 financial results and significant advancements in its pemvidutide clinical programs, particularly for MASH.

Altimmune, Inc. announced positive topline results from its IMPACT Phase 2b trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), demonstrating significant MASH resolution and weight loss with favorable tolerability.

Altimmune has secured a $100 million credit facility with Hercules Capital to support the ongoing development of pemvidutide for liver and cardiometabolic diseases.

Altimmune, Inc. announces the pursuit of two new indications, Alcohol Use Disorder (AUD) and Alcohol-Associated Liver Disease (ALD), for its lead product candidate, pemvidutide.

Altimmune reports financial results for Q4 and full year 2024, highlighting progress with pemvidutide and upcoming milestones.

Altimmune appoints Teri Lawver and Jerome Durso to its Board of Directors, bolstering expertise in commercial strategy, liver disease, and metabolic disorders as the company advances pemvidutide.

Altimmune's pemvidutide showed significant reductions in liver fat content and improvements in lipid profiles in a Phase 1b trial for metabolic dysfunction-associated steatotic liver disease (MASLD).

Altimmune announced the completion of enrollment in its Phase 2b MASH trial and provided updates on its obesity program, including a successful meeting with the FDA.

Altimmune, Inc. has appointed Gregory Weaver as its new Chief Financial Officer, effective November 11, 2024.

Altimmune, Inc. held its 2024 Annual Meeting of Stockholders on September 26, 2024, where directors were elected, the appointment of Ernst & Young LLP as auditor was ratified, and an advisory vote on executive compensation was held.

Altimmune, Inc. announces that director David J. Drutz will not seek re-election at the company's 2024 Annual Meeting of Shareholders.

Altimmune announced its second quarter 2024 financial results, highlighting progress in pemvidutide development for obesity and MASH, with topline data from the Phase 2b IMPACT trial expected in Q1 2025.

Altimmune has appointed Andrew Shutterly as acting CFO after the unexpected death of their CFO, Richard Eisenstadt.

Altimmune announced its first quarter 2024 financial results, highlighting progress in its pemvidutide clinical trials for obesity and MASH, with top-line results for the MASH trial expected in Q1 2025.

Altimmune's pemvidutide shows promising lean mass preservation in a Phase 2 obesity trial, with 74.5% of weight loss from adipose tissue, and the company reports its full year 2023 financial results.